Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis

Ralf Kronenwett; Thorsten Gräf; Frank Neumann; Sabrina Pechtel; Ulrich Steidl; Elena Diaz-Blanco; Rainer Haas

doi:10.1016/j.leukres.2005.12.006

Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis

Ralf Kronenwett, Thorsten Gräf, Frank Neumann, Sabrina Pechtel, Ulrich Steidl, Elena Diaz-Blanco, Rainer Haas

Research output: Contribution to journal › Letter › peer-review

6 Scopus citations

Abstract

In this study, we examined highly enriched CD34+ cells from patients with BCR-ABL-positve CML in chronic phase or blast crisis for the JAK2 V617F activation mutation by sequencing. The cells examined did not bear the mutation irrespective of the disease stage. This finding suggests that the previously described increase of expression and kinase activity of JAK2 in CML cells does not result from the JAK2 V617F activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation.

Original language	English (US)
Pages (from-to)	1323-1324
Number of pages	2
Journal	Leukemia Research
Volume	30
Issue number	10
DOIs	https://doi.org/10.1016/j.leukres.2005.12.006
State	Published - Oct 2006
Externally published	Yes

Keywords

Blast crisis
CD34+ cells
CML
JAK2

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2005.12.006

Cite this

@article{e09f95143bc445d487eb093266439b81,

title = "Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis",

abstract = "In this study, we examined highly enriched CD34+ cells from patients with BCR-ABL-positve CML in chronic phase or blast crisis for the JAK2 V617F activation mutation by sequencing. The cells examined did not bear the mutation irrespective of the disease stage. This finding suggests that the previously described increase of expression and kinase activity of JAK2 in CML cells does not result from the JAK2 V617F activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation.",

keywords = "Blast crisis, CD34+ cells, CML, JAK2",

author = "Ralf Kronenwett and Thorsten Gr{\"a}f and Frank Neumann and Sabrina Pechtel and Ulrich Steidl and Elena Diaz-Blanco and Rainer Haas",

note = "Funding Information: We thank A. Koch and M. Pooten for excellent technical assistance. This work was supported in part by Leuk{\"a}mie Liga e.V. D{\"u}sseldorf and by the University of Duesseldorf. ",

year = "2006",

month = oct,

doi = "10.1016/j.leukres.2005.12.006",

language = "English (US)",

volume = "30",

pages = "1323--1324",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "10",

}

TY - JOUR

T1 - Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis

AU - Kronenwett, Ralf

AU - Gräf, Thorsten

AU - Neumann, Frank

AU - Pechtel, Sabrina

AU - Steidl, Ulrich

AU - Diaz-Blanco, Elena

AU - Haas, Rainer

N1 - Funding Information: We thank A. Koch and M. Pooten for excellent technical assistance. This work was supported in part by Leukämie Liga e.V. Düsseldorf and by the University of Duesseldorf.

PY - 2006/10

Y1 - 2006/10

N2 - In this study, we examined highly enriched CD34+ cells from patients with BCR-ABL-positve CML in chronic phase or blast crisis for the JAK2 V617F activation mutation by sequencing. The cells examined did not bear the mutation irrespective of the disease stage. This finding suggests that the previously described increase of expression and kinase activity of JAK2 in CML cells does not result from the JAK2 V617F activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation.

AB - In this study, we examined highly enriched CD34+ cells from patients with BCR-ABL-positve CML in chronic phase or blast crisis for the JAK2 V617F activation mutation by sequencing. The cells examined did not bear the mutation irrespective of the disease stage. This finding suggests that the previously described increase of expression and kinase activity of JAK2 in CML cells does not result from the JAK2 V617F activation mutation and that transformation into blast crisis is not associated with the occurrence of this mutation.

KW - Blast crisis

KW - CD34+ cells

KW - CML

KW - JAK2

UR - http://www.scopus.com/inward/record.url?scp=33746776854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746776854&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.12.006

DO - 10.1016/j.leukres.2005.12.006

M3 - Letter

C2 - 16442619

AN - SCOPUS:33746776854

SN - 0145-2126

VL - 30

SP - 1323

EP - 1324

JO - Leukemia Research

JF - Leukemia Research

IS - 10

ER -

Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this